ReviewJCO oncology practice2026
Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review.
Review in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most frequent subtype of NETs and their incidence has steadily increased over the past few decades. Patients with GEP-NETs often experience a large symptom burden and decrease in quality of life. Delays in diagnosis and high incidence of metastatic disease are the consequences of a lack of awareness or a lack of understanding of how to manage GEP-NETs among health care professionals. Although surgical resection is the only curative approach for GEP-NETs, many patients are not candidates for surgery. For these patients, new therapies have emerged recently, including radiolabeled therapeutic peptides used to target cancer cells and inhibit tumor growth. Radiolabeled somatostatin analogs, such as [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.